In first remission, high-dose therapy plus stem cell rescue improves time to treatment failure and progression-free survival when compared with maintenance interferon alpha. However, relapse rate does not reach a plateau. Radioimmunotherapy has substantial single-agent activity and when combined with ...
However, MCL is typically an aggressive lymphoma characterized by rapid progression and high relapse rates even with multiagent therapy and is generally is considered incurable, except potentially for those eligible for autologous stem cell transplantation (ASCT) [5–9]. As such, initial decisions ...
(2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood, 105, 2677–2684. Gopal, ...
Mantle Cell Lymphoma (MCL) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MCL is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the ...
Mantle cell lymphoma (MCL) is a therapeutic challenge because of its lower cure rate when compared with other lymphomas such as diffuse large cell lymphoma. The current emphasis in the treatment of newly diagnosed MCL has been on intensifying chemotherapy, but there is no consensus on the need ...
However, patients with a TP53 mutation or high-risk Mantle Cell Lymphoma International Prognostic Index score have an increased relapse rate despite treatment with chemoimmunotherapy that warrants subsequent treatment with Bruton tyrosine kinase (BTK) inhibitors, BCL2 inhibitors or immunomodulators, or CD...
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer ...
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and availa
Methods: MANTLE‐FIRST, an international, retrospective study, evaluated outcomes in patients with MCL who had progressive disease or first relapse when treated upfront with high dose cytarabine (HDAC), followed by autologous stem cell transplantation if appropriate. Response rates, overall survival (...
Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin’s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit, transplant eligible patients, or less intensive chemotherapy ...